StreetInsider.com News Articles

Form 6-K TRINITY BIOTECH PLC For: Jul 22

Wed, 22 Jul 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260722/26798599.html

Form 6-K TRINITY BIOTECH PLC For: Jul 22

Wed, 22 Jul 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260722/26798599.html

Form 6-K TRINITY BIOTECH PLC For: Jul 22

Wed, 22 Jul 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260722/26798542.html

Form 6-K TRINITY BIOTECH PLC For: Jul 22

Wed, 22 Jul 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260722/26798542.html

Trinity Biotech partners with Latch Medical on biosensor-guided drug delivery

Wed, 22 Jul 2026 07:31:20 -0400

Trinity Biotech plc (NASDAQ: TRIB) announced a strategic collaboration agreement with Latch Medical Limited to combine Trinity Biotech's CGM+ wearable biosensor platform with Latch Medical's intradermal drug delivery technology, known as Pharma Latch™.

The collaboration aims to evaluate the development of therapeutic solutions for diabetes, obesity, and other metabolic conditions by pairing real-time metabolic data from the CGM+ platform with Latch Medical's drug delivery system. The companies plan to explore how data generated by CGM+ could be used to guide therapeutic delivery.

As part of the agreement, Trinity Biotech has agreed in principle to make a strategic equity investment in Latch Medical.

Trinity Biotech partners with Latch Medical on biosensor-guided drug delivery

Wed, 22 Jul 2026 07:31:20 -0400

As part of the agreement, Trinity Biotech has agreed in principle to make a strategic equity investment in Latch Medical.

Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology

Wed, 22 Jul 2026 07:30:00 -0400

- Strategic collaboration and equity investment will combine Trinity Biotech's AI-native CGM+ wearable biosensor platform with Latch Medical's innovative intradermal drug delivery technology to develop next-generation metabolic health solutions -

DUBLIN and WILSONVILLE, Ore., July 22, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical and industrial needs, today announced a strategic collaboration agreement with Latch Medical Limited, a medical technology company with an innovative intradermal drug delivery platform ("Pharma Latch™").

The collaboration is intended to combine

Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology

Wed, 22 Jul 2026 07:30:00 -0400

The collaboration is intended to combine

Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology

Wed, 22 Jul 2026 07:30:00 -0400

The collaboration is intended to combine

Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology

Wed, 22 Jul 2026 07:30:00 -0400

The collaboration is intended to combine

Trinity Biotech plans a 1-for-30 reverse ADS split to meet Nasdaq rules

Wed, 22 Jul 2026 07:15:53 -0400

Trinity Biotech plc (NASDAQ: TRIB) announced plans to change the ratio of its American depositary shares, effective at the open of trading on July 24, 2026, on the Nasdaq Global Market.

The Dublin-based company said it will shift the ADS ratio from one ADS representing 20 Class A ordinary shares to one ADS representing 600 Class A ordinary shares. The change carries the same effect as a 1-for-30 reverse ADS split. The company's underlying Class A ordinary shares are not affected.

Trinity Biotech said the ratio change is intended to help the company regain compliance with Nasdaq's $1.00 minimum bid price requirement.

Trinity Biotech plans a 1-for-30 reverse ADS split to meet Nasdaq rules

Wed, 22 Jul 2026 07:15:53 -0400

Trinity Biotech plc (NASDAQ: TRIB) announced plans to change the ratio of its American depositary shares, effective at the open of trading on July 24, 2026, on the Nasdaq Global Market.

Trinity Biotech said the ratio change is intended to help the company regain compliance with Nasdaq's $1.00 minimum bid price requirement.

Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change

Wed, 22 Jul 2026 07:15:00 -0400

DUBLIN, July 22, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), (the “Company”) today announced that it plans to change the ratio of the American depositary shares (“ADSs”) representing its Class A ordinary shares from one (1) ADS representing twenty (20) Class A ordinary shares to one (1) ADS representing six hundred (600) Class A ordinary shares.

For Trinity Biotech Plc ADS holders, the change in the ADS ratio will have the same effect as a one for-thirty reverse ADS split and is intended to i) enable the Company to regain compliance with the

Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change

Wed, 22 Jul 2026 07:15:00 -0400

For Trinity Biotech Plc ADS holders, the change in the ADS ratio will have the same effect as a one for-thirty reverse ADS split and is intended to i) enable the Company to regain compliance with the

Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change

Wed, 22 Jul 2026 07:15:00 -0400

For Trinity Biotech Plc ADS holders, the change in the ADS ratio will have the same effect as a one for-thirty reverse ADS split and is intended to i) enable the Company to regain compliance with the

Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change

Wed, 22 Jul 2026 07:15:00 -0400

For Trinity Biotech Plc ADS holders, the change in the ADS ratio will have the same effect as a one for-thirty reverse ADS split and is intended to i) enable the Company to regain compliance with the

Form 424B3 TRINITY BIOTECH PLC /ADR

Tue, 14 Jul 2026 15:12:00 -0400

si-local-file:///var/storage/secattach/20260714/26767902.html

Form 424B3 TRINITY BIOTECH PLC /ADR

Tue, 14 Jul 2026 15:12:00 -0400

si-local-file:///var/storage/secattach/20260714/26767902.html

Trinity Biotech reports CGM+ data on detecting false glucose lows

Thu, 02 Jul 2026 08:31:48 -0400

Trinity Biotech plc (NASDAQ: TRIB) announced clinical study results showing its CGM+ wearable biosensor platform can identify nocturnal compression-related false low glucose readings, a limitation found in conventional continuous glucose monitoring systems.

The analysis drew on approximately 5,000 hours of device wear data collected from insulin-dependent people with diabetes during a pre-pivotal clinical trial completed in the second quarter of 2026. The company combined glucose measurements with additional physiological signals captured through its proprietary multi-sensor architecture to develop an algorithm that distinguishes false low glucose readings caused by sensor compression during sleep from actual changes in blood glucose levels.

Published academic research

New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring